NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Globus Medical, Inc. (“Globus” or the “Company”) (NYSE: GMED). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Globus and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 8, 2025, ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors, following disappointing financial results for Q1 2025 that led to a significant drop in stock price [1][3]. Financial Performance - On May 8, 2025, Globus reported non-GAAP earnings per share of $0.68, which was $0.06 below consensus estimates [3]. - The company's revenue for Q1 2025 was $598.12 million, missing consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [3]. - Following the announcement of these results, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Company Challenges - The decline in financial performance was attributed to softer Enabling Technology deal closures, temporary supply chain disruptions related to integration, and the timing of international distributor orders, as stated by the President and CEO of Globus [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors [1] Financial Performance - On May 8, 2025, Globus reported non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06 [3] - The company reported revenue of $598.12 million, which was $27.78 million below consensus estimates and represented a 1.4% year-over-year decline [3] - Following the financial results announcement, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 per share on May 9, 2025 [3] Company Challenges - The decline in financial performance was attributed to softer Enabling Technology deal closures, temporary integration-related supply chain disruptions, and the timing of international distributor orders [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors, following disappointing financial results for Q1 2025 that led to a significant drop in stock price [1][3]. Financial Performance - On May 8, 2025, Globus reported non-GAAP earnings per share of $0.68, which was $0.06 below consensus estimates [3]. - The company's revenue for Q1 2025 was $598.12 million, missing consensus estimates by $27.78 million and reflecting a 1.4% decline year-over-year [3]. - Following the announcement of these results, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Company Challenges - The decline in financial performance was attributed to softer deal closures in Enabling Technology, temporary supply chain disruptions related to integration, and the timing of international distributor orders [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. and its officers or directors [1] Financial Performance - On May 8, 2025, Globus reported Q1 2025 financial results, with non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06 [2] - Revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [2] - The decline in performance was attributed to softer Enabling Technology deal closures, temporary supply chain disruptions related to integration, and the timing of international distributor orders [2] Market Reaction - Following the financial results announcement, Globus's stock price dropped by $16.64 per share, or 22.96%, closing at $55.82 per share on May 9, 2025 [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. following disappointing financial results for Q1 2025, which led to a significant drop in the company's stock price [1][3]. Financial Performance - Globus Medical reported non-GAAP earnings per share of $0.68 for Q1 2025, missing consensus estimates by $0.06 [3]. - The company's revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [3]. - Following the announcement of these results, Globus's stock price decreased by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Company Challenges - The decline in financial performance was attributed to several factors, including softer Enabling Technology deal closures, temporary supply chain disruptions related to integration, and the timing of international distributor orders [3].

Core Viewpoint - Globus Medical, Inc. has authorized a share repurchase program of up to $500 million to address the disconnect between its intrinsic value and market valuation, reflecting confidence in its long-term growth and profitability [1][2]. Group 1: Share Repurchase Program - The share repurchase program is aimed at buying back up to $500 million of the company's outstanding common stock [1]. - The timing and number of shares repurchased will be at management's discretion, influenced by market conditions and other factors [2]. - The program will be funded using the company's cash reserves and aligns with its long-term capital allocation strategy [3]. Group 2: Company Overview - Globus Medical is a leading global musculoskeletal solutions company focused on addressing unmet clinical needs and improving patient outcomes [4]. - The company emphasizes innovation, education, and clinical support across various areas including spine, orthopedic trauma, and joint reconstruction [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Globus Medical, Inc. following disappointing financial results for Q1 2025, which led to a significant drop in the company's stock price [1][3]. Financial Performance - Globus Medical reported non-GAAP earnings per share of $0.68 for Q1 2025, missing consensus estimates by $0.06 [3]. - The company's revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and reflecting a 1.4% year-over-year decline [3]. - Following the announcement of these results, Globus's stock price decreased by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3]. Investigation Details - The investigation by Pomerantz LLP is aimed at determining whether Globus and its officers or directors engaged in any fraudulent activities related to securities [1].

Core Viewpoint - Globus Medical reported a decline in revenue and earnings for the quarter ended March 2025, missing Wall Street expectations, indicating potential challenges in financial performance [1][2]. Financial Performance - Revenue for the quarter was $598.12 million, down 1.4% year-over-year, and below the Zacks Consensus Estimate of $628.32 million by 4.81% [1]. - Earnings per share (EPS) were $0.68, a decrease from $0.72 in the same quarter last year, and fell short of the consensus estimate of $0.74 by 8.11% [1]. Geographic Revenue Breakdown - International revenue was reported at $114.26 million, which is 7.7% lower than the three-analyst average estimate of $127.52 million [4]. - U.S. revenue stood at $483.86 million, slightly up by 0.2% year-over-year, but below the average estimate of $510.72 million [4]. Product Category Performance - Net sales from Enabling Technologies were $22.19 million, significantly lower than the estimated $38.79 million, reflecting a year-over-year decline of 30.6% [4]. - Musculoskeletal Solutions generated $575.93 million in sales, which was marginally above the year-ago figure by 0.2%, but still below the estimated $598.85 million [4]. Stock Performance - Shares of Globus Medical have returned -3.7% over the past month, contrasting with the Zacks S&P 500 composite's increase of 11.3% [3]. - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3].

Core Viewpoint - Globus Medical reported quarterly earnings of $0.68 per share, missing the Zacks Consensus Estimate of $0.74 per share, and showing a decline from $0.72 per share a year ago, indicating an earnings surprise of -8.11% [1][2] Financial Performance - The company posted revenues of $598.12 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 4.81%, and down from $606.67 million year-over-year [2] - Over the last four quarters, Globus Medical has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Performance - Globus Medical shares have declined approximately 13.5% since the beginning of the year, compared to a decline of -4.3% for the S&P 500 [3] - The current Zacks Rank for Globus Medical is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.86 on revenues of $671.54 million, and for the current fiscal year, it is $3.45 on revenues of $2.68 billion [7] - The estimate revisions trend for Globus Medical is mixed, and future changes in estimates will be closely monitored following the recent earnings report [6][7] Industry Context - The Medical - Instruments industry, to which Globus Medical belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]